Booster Sessions after Cognitive-Behavioural Group Therapy for Panic Disorder: Impact on Resilience, Coping, and Quality Of Life

Ana Cristina Wesner, Juliana Braga Gomes, Tatiana Detzel, Luciano S. P. Guimarães and Elizeth Heldt

Federal University of Rio Grande do Sul and Hospital de Clínicas de Porto Alegre, Brazil

Background: Panic disorder (PD) has a chronic nature, especially as a result of maladaptive coping strategies to deal with stressful events. Aims: To evaluate the impact of booster sessions with cognitive techniques on coping strategies, resilience, and quality of life (QoL) in patients previously submitted to standard cognitive-behavioural group therapy (CBGT) for PD. Method: A controlled clinical trial with 44 patients with PD (intervention = 20; control = 24) who had previously completed a 12-week CBGT protocol. PD, anxiety, and depression severity symptoms were assessed at baseline and 1, 6, and 12 months after the booster sessions. Coping strategies, resilience, and QoL were assessed by Coping Strategies Inventory (CSI), Resilience Scale, and WHOQOL-BREF respectively. Results: Over time, a significant improvement in PD and depression symptoms was observed in both groups. A significant increase in the QoL social relations domain was found in the booster group, considering a time/group interaction. Coping and other QoL domains did not change after the booster sessions. Changes in resilience were dependent on the intensity of symptoms, with negative but non-significant correlations. Conclusions: The improvement in PD and depression symptoms for both groups may be a result of the group format of the intervention. Group booster sessions after CBGT are useful to maintain the benefits obtained with CBGT.

Keywords: Panic disorder, resilience, quality of life, coping, cognitive-behavioural therapy.

Introduction

Panic disorder (PD) is characterized by the presence of sudden, unexpected anxiety attacks, accompanied by physical and affective symptoms, fear of having additional attacks, and avoidance of places and situations where previous attacks have occurred (American Psychiatric Association, 2002). Although most patients report a precipitating factor related to the onset of disease (Lteif and Mavissakalian, 1995; Manfro et al., 1996; Moitra et al., 2011), PD persists even after the disappearance of this stressor, suggesting a chronic course associated with high morbidity and negative impact on quality of life (QoL) (Kessler et al., 2006).

Reprint requests to Elizeth Heldt, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2350, Room 400N, ZIP code: 90035-903, Porto Alegre, RS, Brazil. E-mail: eliz.h@globo.com

Despite the evidence showing the efficacy of pharmacological treatment (Pollack, 2005) for PD, the mechanisms underlying the response to treatment are not fully understood and treatment resistance is not uncommon. In that context, cognitive-behavioural treatment (CBT) has proven useful to treat PD, both as adjunctive and main treatment strategy (Otto and Deckerbach, 1998; Pollack, 2005).

The role of CBT in the treatment of PD relates to the hypothesis that maladaptive coping strategies to deal with stressful events may trigger both the appearance (Manfro et al., 1996) and maintenance of symptoms (Moira et al., 2011) or relapse of PD (Hino, Takeuchi and Yamanouchi, 2002). A previous study showed that patients with PD use less adaptive and effective coping strategies compared to the control group with individuals without mental disease (Savoia and Bernik, 2004).

Psychosocial interventions, and especially cognitive techniques, can be used to help patients learn coping strategies (Hyun, Nam and Kim, 2010; Songprakun and McCann, 2012; Padesky and Mooney, 2012), even though the changes and the use of coping strategies may also depend on previous experiences and personal resources (Taylor and Stanton, 2007). For example, psychosocial intervention for stress management has a positive effect on depressive and anxiety symptoms, but a change in coping strategies does not always occur (Kennedy, Duff, Evans and Beedie, 2003; Kuper, Gallop and Greenfield, 2010).

In our setting, the efficacy of cognitive-behavioural group therapy (CBGT) has been demonstrated in a 12-session CBGT protocol emphasizing information, cognitive restructuring, and exposure to feared sensations of anxiety and panic (interoceptive exposure), as well as stepwise exposure to agoraphobic situations. In that study, the effect size of CBGT was moderate to large for different outcomes after acute treatment (Heldt et al., 2003) as measured one year after the intervention (Heldt et al., 2006). However, in the 2-year follow-up, residual symptoms of anxiety and occurrence of recent stressful life events were observed, so predicting PD relapse (Heldt et al., 2011).

Based on these findings, another study was conducted to identify the effect of a 12-session CBGT protocol on the coping strategies of patients with PD, comparing these individuals with control patients with no mental disorders (Wesner et al., 2014). Patient assessments following CBGT revealed significant correlations between the use of adaptive coping strategies, decreased anticipatory anxiety and panic attacks. However, the use of coping strategies still differed significantly between patients and controls. We concluded that the acquisition of new cognitive strategies, such as problem-solving and resilience training – the development of the ability to adapt to and overcome stressful life events and adversities (Leopold and Greve, 2009) – could be implemented in standard CBGT protocols or subsequent booster sessions to change maladaptive coping styles and prevent PD relapse (Heldt et al., 2011; Wesner et al., 2014).

The present study aims to evaluate the impact of cognitive booster sessions for coping and resilience training after standard CBGT for the treatment of PD.

Method

Participants

Forty-eight patients from the Anxiety Disorders Program (PROTAN) at Hospital de Clínicas de Porto Alegre (HCPA) who received 12 CBGT sessions for PD previously were invited

to participate in the present trial. The inclusion criteria for the CBGT group as well as the measures of symptom severity and the assessment of the coping strategies used before and after the intervention have been described elsewhere (Wesner et al., 2014). After the 12 CBGT sessions, participants were found to display significant improvements with large effect sizes (ES = 0.83 to 1.53) in anticipatory anxiety, agoraphobia, panic attacks, depressive symptoms and general anxiety. After treatment, 36 (75%) used antidepressants and 16 (33%) had been prescribed benzodiazepines.

For the present study, inclusion criteria were participation in the CBGT protocol between 2006 and 2009 and diagnosis of PD with or without agoraphobia based on the Mini International Neuropsychiatric Interview (MINI) (Amorin, 2000). Exclusion criteria included psychotic symptoms, significant clinical disease or disabling chronic disease in the last 6 months before the trial.

Patients were allocated to a booster group (4 booster sessions) or control group (2 educational sessions) using a draw system. Booster and educational sessions were carried out in September and October 2010. Follow-up assessments were conducted until October 2011. The study was approved by the Institutional Review Board and Research Ethics Committee (protocol no. 100136). All patients provided written informed consent.

Measures

Independent evaluators blinded to the patient group carried out the assessment of symptom severity. After that, patients in both groups answered the self-report assessments at baseline, 1, 6, and 12 months.

Assessment of PD severity and treatment response was based on the Panic Disorder Severity Scale (PDSS) (Shear et al., 1997), a 7-item instrument that takes into consideration the intensity and frequency of panic attacks, degree of anticipatory anxiety, anxiety sensitivity, level of phobic avoidance, and social and professional impairment. The Hamilton-anxiety (HAM-A) (Hamilton, 1959) and Beck Depression Inventory (BDI) (Gorenstein, Andrade, Vieira-Filho, Tung, Artes, 1999) were used to assess anxiety and depressive symptoms respectively. The scales were applied at baseline, 1, 6, and 12 months in both groups, by independent interviewers blind to the intervention condition.

Coping strategies, resilience, and quality of life were measured by validated self-report scales as mentioned above. The Coping Strategies Inventory (CSI) (Savoia, Santana and Mejias, 1996) was used to identify the thoughts and actions used by individuals to deal with internal or external demands of a specific stressful event. This 66-item scale covers eight different dimensions grouped into three types of strategy: 1) problem-focused strategy: confrontation (aggressiveness, hostility, and taking risk to change the situation), social support (information, support, and emotional basis), problem solving, and positive reappraisal (creating a positive meaning, focus on personal growth); 2) emotion-focused strategy: distancing (detachment and minimization of the situation), acceptance of responsibility (recognizing their role in the problem), escape and avoidance (efforts to escape or avoid the situation); and 3) both: self-control (regulation of one's own feelings and actions).

QoL was assessed by the World Health Organization Quality of Life Instrument – Short Version (WHOQOL-Bref) (Fleck et al., 2000), consisting of 26 questions, 2 about general QoL and the remaining 24 covering physical, psychological, social relations, and environment

domains. The scale provides scores ranging from 1–100 in each domain, with higher scores associated with better QoL.

The Resilience Scale is used to measure levels of positive psychosocial adaptation to major life events (Pesce et al., 2005). It has 25 positively worded Likert items with scores from 1 (strongly disagree) to 7 (strongly agree). The resulting scores range from 25 to 175 points, with higher values indicating a high resilience.

Intervention

In addition to the 12 CBGT sessions conducted previously (Wesner et al., 2014), in which the focus was PD symptoms, in the present study the booster group participated in 4 weekly sessions lasting 90 minutes each, involving psychoeducation and coping techniques such as problem-solving and resilience training. Briefly, the first session was dedicated to recap PD psychoeducation and diaphragmatic breathing skills. In the second session, coping and problem-solving techniques were introduced (Saffi, Savoia and Lutufo Neto, 2008). The third session aimed to promote resilience strategies through causal analysis, emotional regulation, impulse control, optimism, empathy and self-efficacy (Pesce et al., 2005). The fourth and final session focused on the identification of life stressors and their effects.

Patients in the control group participated in two sessions about healthy life habits, such as physical activities and its benefits; healthy eating and sleep hygiene; leisure and personal care. These 90 minute-sessions were held one month apart.

Statistical analysis

Categorical variables are expressed as absolute and relative frequency (percent). Quantitative variables with symmetric distribution are expressed as mean and standard deviation (SD) or standard error (SE). Group comparison of socio-demographic variables was performed using the t-test and Fisher's exact test. Generalized estimating equations (GEE) analysis (Liang and Zeger, 1986) was used for group comparison to verify the impact of booster sessions over 12 months. If significant, the factors were compared using Bonferroni post-hoc analysis. Adjusted GEE was again used with PDSS, HAM-A, and BDI to check if the significant changes were mediated by the symptoms. Effect size (ES) was measured using Cohen's d. Analyses were performed by SPSS version 18.0. Results were considered significant when p < .05.

Results

A group of 44 subjects was selected, with 20 (45%) allocated to the intervention group and 24 (55%) to the control group. Three individuals refused to participate, and one participant did not meet the inclusion criteria. The groups had similar socio-demographic characteristics. As for clinical characteristics, antidepressant use was significantly more common in the control group vs. the intervention group (p = .046). Time between CBGT and booster sessions varied from 1 to 4 years. There was no difference between the groups regarding past CBGT (p = .385) (see Table 1).

Data regarding initial symptom severity is presented in Table 2. The intervention group had more severe symptoms of PD, anxiety and depression. However, between-group differences at baseline were not statistically significant. This may be attributed to the observed variability

Table 1. Socio-demographic and clinical characteristics: comparison between intervention and control
groups

	8 F -				
	Intervention group	Control group $n = 24 (55\%)$			
Variables*	n = 20 (45%)				
Socio-demographic					
Gender					
Female	15 (75)	19 (79)			
Age	44.3 (11)	38.0 (10.7)			
Formal education (years)	12.1 (3.3)	12.3 (3.8)			
Marital status					
Single	5 (25)	9 (37)			
Married/with partner	11 (55)	13 (54)			
Separated/divorced	3 (15)	2 (8)			
Widow/widower	1 (5)	=			
Clinical					
Comorbidities					
Mood disorders**	16 (80)	19 (79)			
Anxiety disorders***	14 (58)	15 (75)			
Medication					
Antidepressant	9 (45)#	18 (75)#			
Benzodiazepines	10 (50)	13 (54)			
Psychotherapy					
Current	2 (10)	3 (12.5)			
Past CBGT (months)	36.1 (15.5)	32 (15.4)			

Notes: * Continuity variables were presented by means and standard deviation (*SD*). *T* test was used. Categorical variables were presented by frequency and percent. Fisher's Test was used:

CBGT = Cognitive behaviour group therapy

estimated by the standard error [PDSS: intervention = 16.6(1.34) and control = 11.9(1.53); HAM-A: intervention = 27.1(1.61) and control = 24.5(2.39); BDI: intervention = 23.6(2.89) and control = 16.2(1.97)]. In relation to symptom severity after the booster sessions, significant improvement over time was found for the following variables: PD (PDSS) [$(p_{\text{time*group}} = .398; p_{\text{group}} = .145; p_{\text{time}} < .001)$], anxiety (HAM-A) [$(p_{\text{time*group}} = .272; p_{\text{group}} = .189; p_{\text{time}} < .001)$], and depression (BDI) [$(p_{\text{time*group}} = .488; p_{\text{group}} = .057; p_{\text{time}} < .018)$], with a large effect size. No difference was found on interaction between the intervention and control groups.

The impact of each intervention on resilience strategies and coping were measured over time. A significant increase in resilience was found at 1 month in the control group. The difference occurred on the interaction [control: baseline mean (SD) = 105.9 (4.91) vs. 1 month = 116.1 (3.96); intervention: baseline = 108 (5.67) vs. 1 month = 107.5 (5.86); $p_{\text{time*group}} = 0.039$)]. However, a significant drop in control group resilience was observed again after 12 months of follow-up [control = 99.8(7.68)]; intervention = 115.2(5.08)]. In the booster group, a non-significant increase in resilience was observed after 12 months (see

^{**}Mood disorders: current and past depression or dysthymia;

^{***}Anxiety disorders: generalized anxiety disorder, social anxiety disorder or obsessive-compulsive disorder; # p<.05

		G					
Measures	Time	Control Mean (SE)	Intervention Mean (SE)	General [#] Mean (SE)	ES	CI95	%
PDSS	Baseline 1 month 6 months 12 months	11.9 (1.53) 10.4 (1.59) 11.8 (1.84) 10 (1.40)	16.6 (1.34) 13.7 (1.41) 12.3 (1.60) 11.6 (1.48)	14.2 (1.02) ^a 12.0 (1.06) ^b 12.0 (1.22) ^{ab} 10.7 (1.02) ^b	4.8	3.6	5.9
Anxiety (HAM-A)	Baseline 1 month 6 months 12 months	24.5 (2.39) 18.9 (1.94) 18.4 (2.68) 20.4 (2.32)	27.1 (1.61) 22.8 (2.37) 24 (2.58) 23.3 (2.42)	25.7 (1.61) ^a 19.8 (1.53) ^b 21.2 (1.86) ^{ab} 21.8 (1.68) ^b	3.5	2.5	4.4
Depression (BDI)	Baseline 1 month 6 months 12 months	16.2 (1.97) 13.7 (1.82) 15.9 (2.66) 13 (2.41)	23.6 (2.89) 21.9 (2.67) 19.5 (2.85) 18.2 (3.06)	19.8 (1.75) ^a 17.7 (1.61) ^{ab} 17.6 (1.95) ^{ab} 15.5 (1.95) ^b	4.0	2.9	5.0

Table 2. Symptom severity outcome measures across the study period

Notes: Abbreviations: CI95%, 95% Confidence Interval; GEE, Generalized Estimating Equations; SE, Standard Error; PDSS, Panic Disorder Severity Scale; HAM-A, Hamilton Anxiety; BDI, Beck Depression Inventory.

Different letters (a,b) indicate statistical significant results at 0.05 level of significance in sequential Bonferroni multiple comparison adjustment; # Independent overall group mean over time.

ES – Effect size (Cohen's formula) between baseline and the 12-month assessment in the General mean score.

Figure 1). The effect size for resilience was 0.4 (IC95%: [-0.2; 1.0]). No significant changes on coping strategies were observed (Table 3).

QoL assessed with WHOQOL-Bref was significantly higher in the social relations domain for the booster group after 6 months [$(p_{\text{time*group}} < .001)$]. No significant association was found between any of the other QoL domains and the booster or control interventions (Table 4).

Considering the hypothesis that the change in resilience and QoL could be mediated by the severity of PD, anxiety, and depression symptoms, an adjusted analysis was performed for these aspects. It was found that resilience was not significant for HAM-A ($p_{\text{time*group}} = .194$), BDI ($p_{\text{time*group}} = .134$), and PDSS ($p_{\text{time*group}} = .099$), confirming that the symptoms are mediators of resilience levels. In order to establish the direction of the effect, a correlation test was performed. A negative correlation was identified between higher levels of resilience and less intense symptoms (Figure 2).

The social relations domain of QoL remained significant after adjustment for anxiety ($p_{\text{time*group}} < .001$), depression ($p_{\text{time*group}} = .022$), and PD symptoms ($p_{\text{time*group}} = .032$), demonstrating that the change in QoL in this domain was not mediated by the presence of symptoms after the booster sessions.

Discussion

The results of this study demonstrate that the use of booster sessions after CBGT significantly improved PD, anxiety, and depression symptoms. In spite of random allocation, the




Figure 1. Resilience results during the booster sessions and after 12 months of follow-up

Table 3. Coping strategies results during the booster sessions and 12 months of follow-up

		GEE time effect						
Measures	Group	Baseline Mean (SE)	1 month Mean (SE)	6 months Mean (SE)	12 months Mean (SE)	ES	CI9	5%
Coping straregies								
Confrontive	Control	4.7 (0.57)	4.1 (0.64)	4.3 (0.58)	4.3 (0.63)	1.4	0.7	2.0
	Intervention	4.7 (0.68)	4.6 (0.68)	5.1 (0.80)	3.8 (0.64)			
Distancing	Control	5.8 (0.76)	6.2 (0.57)	5.1 (0.70)	5.2 (0.80)	2.9	2.0	3.7
_	Intervention	6.4 (0.62)	6.8 (0.63)	7.2 (0.74)	5.8 (0.61)			
Social support	Control	8.5 (0.78)	8.5 (0.81)	8.3 (0.81)	7.9 (0.87)	1.8	1.1	2.4
	Intervention	8.4 (1.01)	8.2 (1.09)	7.4 (0.99)	6.9 (1.02)			
Acceptance responsibility	Control	8.1 (0.90)	9 (0.69)	7.4 (0.83)	7.6 (0.86)	3.1	2.2	3.9
	Intervention	10.1 (0.91)	9.8 (0.88)	9.3 (0.83)	9.4 (1.03)			
Escape and avoidance	Control	3.4 (0.36)	3.2 (0.30)	3.3 (0.35)	3.4 (0.41)	1.8	1.1	2.5
-	Intervention	3.8 (0.36)	3.6 (0.42)	3.3 (0.41)	3.2 (0.40)			
Problem solving	Control	4.5 (0.52)	4.6 (0.45)	4.5 (0.56)	5.1 (0.62)	0.8	0.1	1.4
	Intervention	4.6 (0.68)	4.9 (0.69)	5 (0.82)	4.8 (0.58)			
Positive reappraisal	Control	10.5 (1.22)	10.6 (0.96)	10.4 (1.18)	10.8 (1.14)	0.7	0.0	1.3
• •	Intervention	10.1 (1.19)	9.8 (1.12)	10.2 (1.45)	11.2 (1.23)			
Self-control	Control	4.9 (0.51)	5.9 (0.56)	5.8 (0.59)	6.2 (0.64)	3.7	2.7	4.6
	Intervention	6.3 (0.70)	6 (0.65)	7.1 (0.68)	6.1 (0.70)			

Notes: GEE - Generalized Estimating Equations; SE - Standard Error.

ES- Effect size (Cohen's formula) for the higher and lower mean observed between time and group Different symbols (#*) indicate statistical significant results at .05 level of significance in sequential Bonferroni multiple comparison adjustment.




Figure 2. Correlation between resilience and the booster or control intervention considering the severity of PD (PDSS), anxiety (HAM-A), and depression (BDI) symptoms

		GEE time effect						
Domains	Group	Baseline Mean (SE)	1-month Mean (SE)	6-month Mean (SE)	12-month Mean (SE)	ES	S CI95%	
Physical	Control	48.1 (4.17)	51.5 (4.2)	47.6 (4.51)	49.0 (4.21)	0.6	0.0	1.2
	Intervention	43.4 (3.84)	40.3 (3.71)	44.6 (4.51)	47.8 (3.46)			
Psychological	Control	51.0 (3.53)	54.6 (3.34)	51.3 (3.97)	49.2 (4.57)	0.6	0.0	1.2
	Intervention	44.0 (4.25)	44.6 (3.81)	48.1 (4.51)	49.4 (3.67)			
Social relations	Control	58.0 (3.84)#*	55.7 (3.23)#*	49.2 (5.48)#*	51.3 (5.72)#*	0.7	0.1	1.3
	Intervention	44.6 (4.2)#	49.3 (4.31)#*	55.3 (4.97)*	54.4 (4.22)#*			
Environment	Control	61.9 (3.04)	61.9 (2.75)	56.5 (4.81)	58.0 (5.83)	0.5	-0.1	1.1
	Intervention	61.5 (4.29)	59.0 (4.47)	60.0 (4.83)	67.5 (3.97)			
General QoL	Control	57.2 (4.10)	64.5 (3.73)	54.1 (5.69)	51.0 (6.29)	0.6	0.0	1.2
	Intervention	51.8 (4.78)	51.8 (5.25)	52.5 (5.49)	55.0 (4.63)			

Table 4. Quality of life results during the booster sessions and 12 months of follow-up

Notes: GEE- Generalized Estimating Equations; SE- Standard Error.

ES- Effect size (Cohen's formula) for the higher and lower mean observed between time and group Different symbols (#*) indicate statistical significant results at 0.05 level of significant in sequential Bonferroni multiple comparison adjustment.

participants in the intervention group were found to have more severe symptoms at baseline than control participants, and this difference was not statistically significant. However, participants in the intervention group also used fewer medications than control individuals. As such, it is possible that the lower symptom severity observed in the control group may be associated with the increased use of PD medication, which is effective in controlling symptoms such as panic attacks and anxiety (Pollack, 2005). The finding of an improvement in symptoms following booster sessions in the intervention group is in agreement with previous studies which show that, even in patients with severe and medication-resistant symptoms, cognitive and behavioural techniques can successfully improve symptoms of PD (Heldt et al., 2003, 2006).

A non-significant increase in resilience was also observed in the booster group after 12 months, whereas the improvement in resilience observed after the first month in the control group did not last over time. Also, resilience was found to be dependent on symptoms. This is in line with a recent study that demonstrated a positive association between resilience and psychological wellbeing and a negative association with anxiety and depression symptoms (Haddadi and Besharat, 2010). Furthermore, the cognitive techniques used to promote resilience in the intervention group (and not in the control group) led to the improvement of individual skills and interpersonal relationships, which are developed throughout time.

Regarding coping strategies, significant changes were not found as a result of the booster sessions. A similar finding has been reported in studies using a brief intervention based on the coping theory (Kennedy et al., 2003). In another brief intervention study with HIV-positive patients, no changes in coping were observed at the end of the intervention; however, there was reduction in anxiety and depressive symptoms compared to control group. Also, patients who underwent maintenance sessions for one additional year experienced a significant increase

in coping self-efficacy (Chesney, Chambers, Taylor, Johnson and Folkman, 2003). In our study, an increase in resilience levels was observed over time in the intervention group, unlikely given what happened to the control group, even if not significant. Indeed, resilience may be developed through new abilities to perceive, interpret, and overcome challenges and difficulties (Grotberg, 2005).

The social relations domain of QoL for the booster group was significantly higher at 6 months. After that, it remained stable until the 12th month of follow-up. However, the change recorded for the social relations domain was not associated with improvement in PD severity or anxiety and depression symptoms. Considering that improvement in symptoms occurred in both groups, our hypothesis is that the change in resilience in the intervention group, even if not significant, may have produced positive effects in terms of social relations during the follow-up period (Grotberg, 2005).

A significant improvement in PD and in anxiety and depressive symptoms in the control group, which received two sessions with lectures about healthy lifestyle, may be related to benefits of group therapy. Previous studies demonstrated that the group format is associated with clinically significant improvement for patients with anxiety and depression (Oei and Free, 1995; Oei, Llamas and Devilly, 1999). Regardless of the intervention given to the control or booster groups, it is known that group therapies promote the exchange of experiences, generating a therapeutic environment of universality, altruism, and reduced stigma and isolation (Schmalisch, Bratiotis and Muroff, 2010).

Other non-specific factors in the CBGT technique, such as therapeutic alliance and cohesion, may also produce equivalent improvement in outcomes (Oei and Browne, 2006; Yalom and Leszcz, 2006). Besides, the interventions applied to both groups were useful to stimulate positive psychological states, socialization, sharing of information, and catharsis (Woody and Adessky, 2002; Yalom and Leszcz, 2006). Additionally, all study participants had previously received CBGT (Wesner et al., 2014), and their familiarity with the exposure techniques used may have increased their use by group participants.

It is also important to highlight the role of hope. Patients who agree to participate in research relating to their disorder are looking for help; therefore, even if allocated to control groups, they may express emotions and cognitions related to their hope for improvement, which may contribute to clinical improvement (Snyder et al., 2000).

Some limitations of this study must be considered, such as the small sample size and the large number of statistical comparisons. Furthermore, results with large effect sizes, but not significant, might suggest the need for research with higher power. The use of self-administered instruments can also be considered a limitation, because patients may have interpreted some items differently. Moreover, applying these instruments repeatedly over a short period of time might have caused systematized answers. The fact that the intervention was brief could explain the lack of significance in changes such as that noted for resilience. Additional limitations were the different number of sessions in the control vs. booster groups and higher use of antidepressants by control group participants. Besides, we are unable to say how people fared between the end of CBGT and the start of boosters as we did not use the same measures. If we had used the same measures then we could have analyzed how the change between end of original treatment and start of boosters affects the impact of the boosters. This would be helpful in future studies.

In conclusion, in patients participating in CBGT for PD, the gains obtained may be maintained with group booster sessions, especially in terms of resilience, and quality of life.

Further efficacy studies should focus on the combination of specific resilience techniques with standard CBGT.

Acknowledgements

This study was partially funded by Fundação de Incentivo a Pesquisa and Eventos do Hospital de Clínicas de Porto Alegre (FIPE-HCPA) and CAPES scholarship to Doctorate (JBG) and Master (ACW) degree.

References

- American Psychiatric Association (2002). Manual Diagnóstico e Estatístico de Transtornos Mentais (DSM-IV-TR) (4^a. ed.) Porto Alegre: Artmed.
- Amorin, P. (2000). International Neuropsychiatric Interview (MINI): validation of a short structured diagnostic psychiatric interview. Revista Brasileira de Psiquiatria, 22, 106–115. doi: 10.1590/S1516-44462000000300003
- Chesney, M. A., Chambers, D. B., Taylor, J. M., Johnson, L. M. and Folkman, S. (2003). Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention. *Psychosomatic Medicine*, 65, 1038–1046. doi: 10.1097/01.PSY.0000097344.78697.ED
- Fleck, M. P., Louzada, S., Xavier, M., Chachamovich, E., Vieira, G., Santos, L., et al. (2000). Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-bref. *Revista de Saúde Pública*, 32, 178–183. doi: 10.1590/S0034-89102000000200012
- **Gorenstein, C., Andrade, L., Vieira-Filho, A. H., Tung, T. C. and Artes, R.** (1999). Psychometric properties of the Portuguese version of the Beck Depression Inventory on Brazilian college students. *Journal of Clinical Psychology*, *55*, 553–562. doi: 10.1002/(SICI)1097-4679.
- Grotberg, E. H. (2005). Novas tendências em resiliência. In A. Melillo et al., *Resiliência: descobrindo as próprias fortalezas*. Porto Alegre: Artmed.
- Haddadi, P. and Besharat, M. A. (2010). Resilience, vulnerability and mental health. Procedia Social and Behavioral Sciences, 5, 639–642. doi: 10.1016/j.sbspro.2010.07.157
- **Hamilton, M.** (1959). The assessment of anxiety states by rating. *British Journal of Medical Psychology*, 32, 50–55. doi: 0.1111/j.2044-8341.1959.tb00467.x
- Heldt, E., Manfro, G. G., Kipper, L., Blaya, C., Maltz, S., Isolan, L., et al. (2003). Treating medication-resistant panic disorder: predictors and outcome of cognitive-behavior therapy in a Brazilian public hospital. *Psychotherapy and Psychosomatics*, 72, 43–48. doi: 10.1159/000067188
- Heldt, E., Manfro, G., Kipper, L., Blaya, C., Isolan, L. and Otto, M. W. (2006). One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: outcome and predictors of remission. *Behaviour Research and Therapy*, 44, 657–665. doi: 10.1016/j.brat.2005.05.003
- Heldt, E., Kipper, L., Blaya, C., Salum, G. A., Hirakata, V. N., Otto, M. W., et al. (2011). Predictors of relapse in the second follow-up year post cognitive-behavior therapy for panic disorder. *Revista Brasileira de Psiquiatria*, 33, 23–29. doi: 10.1590/S1516-44462010005000005
- **Hino, T., Takeuchi, T. and Yamanouchi, N.** (2002). A 1-year follow-up study of coping in patients with panic disorder. *Comprehensive Psychiatry*, 43, 279–284. doi: 10.1053/comp.2002.33495
- **Hyun, M. S., Nam, K. A. and Kim, M. A.** (2010). Randomized controlled trial of a cognitive-behavioral therapy for at-risk Korean male adolescents. *Archives of Psychiatric Nursing*, 24, 202–211. doi: 10.1016/j.apnu.2009.07.005.

- **Kennedy, P., Duff, J., Evans, M. and Beedie, A.** (2003). Coping effectiveness training reduces depression and anxiety following traumatic spinal cord injuries. *British Journal of Clinical Psychology*, 42, 41–52. doi: 10.1348/014466503762842002
- Kessler, R. C., Chiu, W. T., Jin, R., Ruscio, A. M., Shear, K. and Walters, E. E. (2006). The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. *Archives of General Psychiatry*, 63, 415–424. doi: 10.1001/archpsyc.63.4.415.
- **Kuper, L. E., Gallop, R. and Greenfield, S. F.** (2010). Changes in coping moderate substance abuse outcomes differentially across behavioral treatment modality. *American Journal Addictions*, 19, 543–549. doi: 10.1111/j.1521-0391.2010.00074.x.
- **Leopold, B. and Greve, W.** (2009). Resilience: a conceptual bridge between coping and development. *European Psychologist*, 14, 40–50. doi: 10.1027/1016-9040.14.1.40
- Liang, K.-Y. and Zeger, S. L. (1986). Longitudinal data analysis using generalized linear models. *Biometrika*, 73, 13–22. doi: 10.1093/biomet/73.1.13
- Lteif, G. N. and Mavissakalian, M. R. (1995). Life events and panic disorder/agoraphobia. Comprehensive Psychiatry, 36, 118–122. doi: 10.1016/S0010-440X (95) 90106-X
- Manfro, G. G., Otto, M. W., Mcardle, E. T., Worthington III, J. J., Rosenbaum, J. F. and Pollack, M. H. (1996). Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. *Journal of Affective Disorders*, 41, 135–139. doi: 10.1016/S0165-0327 (96) 00081-X
- Moitra, E., Dyck, I., Beard, C., Bjornsson, A. S., Sibrava, N. J., Weisberg, R. B., et al. (2011). Impact of stressful life events on the course of panic disorder in adults. *Journal of Affective Disorders*, 134(1–3), 373–376. doi: 10.1016/j.jad.2011.05.029
- **Oei, T. P. S. and Browne, A.** (2006). Components of group processes: have they contributed to the outcome of mood and anxiety disorder patients in a group cognitive-behaviour therapy program? *American Journal Psychotherapy*, 60, 53–70.
- Oei, T. P. S. and Free, M. L. (1995). Do cognitive-behavior therapies validate cognitive models of mood disorders: a review of the empirical evidence. *International Journal of Psychology*, 30, 145–179. doi: 10.1080/00207599508246564
- Oei, T. P. S., Llamas, M. and Devilly, G. J. (1999). The efficacy and cognitive processes of cognitive behaviour therapy in the treatment of panic disorder with agoraphobia. *Behavioural and Cognitive Psychotherapy*, 27, 63–88.
- **Otto, M. and Deckerbach, T.** (1998). Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. In J. F. Rosenbaum and M. H. Pollack (Eds), *Panic Disorder and its Treatment*. New York: Marcel Dekker.
- Padesky, C. A. and Mooney, K. A. (2012). Strengths-Based Cognitive-Behavioural Therapy: a four-step model to build resilience. Clinical Psychology and Psychotherapy, 19, 283–290. doi: 10.1002/cpp.1795
- Pesce, R. P., Assis, S. G., Avanci, J. Q., Santos, N. C., Malaquias, J. V. and Carvalhaes, R. (2005). Cross-cultural adaptation, reliability and validity of the resilience scale. *Caderno de Saúde Pública*, 21, 436–448. doi: 10.1590/S0102-311'2005000200010
- **Pollack, M. H.** (2005). The pharmacotherapy of panic disorder. *The Journal of Clinical Psychiatry*, 66(Suppl. 4), 23–27.
- Saffi, F., Savoia, M. and Lutufo Neto, F. (2008). Terapia comportamental e cognitivo-comportamental. In A. Cordioli et al. (Ed.), *Psicoterapias: abordagens atuais*. Porto Alegre: Artmed.
- Savoia, M. G. and Bernik, M. (2004). Adverse life events and coping skills in panic disorder. *Revista do Hospital das Clinicas Faculdade de Medicina Universidade de São Paulo*, 59(6), 337–340. doi: 10.1590/S0041-87812004000600005
- Savoia, M. G., Santana, P. R. and Mejias, N. P. (1996). Adaptação do inventário de estratégias de coping de Folkman e Lazarus para o português. *Revista Psicologia USP*, 7(1/2), 183–201.

- Schmalisch, C. S., Bratiotis, C. and Muroff, J. (2010). Processes in group cognitive and behavioral treatment for hoarding. *Cognitive and Behavioral Practice*, 17, 414–425. doi: 10.1016/j.cbpra.2009.08.005
- Shear, M. K., Brown, T. A., Barlow, D. H., Money, R., Sholomskas, D. E., Woods, S. W., et al. (1997). Multicenter collaborative panic disorder severity scale. *American Journal of Psychiatry*, 154, 1571–1575.
- Snyder, C. R., Ilardi, S. S., Cheavens, J., Michael, S. T., Yamhure, L. and Sympson, S. (2000). The role of hope in cognitive-behavior therapies. *Cognitive Therapy and Research*, 24, 747–762. doi: 10.1023/A: 1005547730153
- **Songprakun, W. and McCann, T. V.** (2012). Effectiveness of a self-help manual on the promotion of resilience in individuals with depression in Thailand: a randomised controlled trial. *BMC Psychiatry*, 12, 1–10. doi: 10.1186/1471-244X-12-12
- **Taylor, S. E. and Stanton, A. L.** (2007). Coping resources, coping processes, and mental health. *Annual Review of Clinical Psychology*, 3, 377–401. doi: 10.1146/annurev.clinpsy.3.022806.091520
- Wesner, A. C., Gomes, J. B., Detzel, T., Blaya, C., Manfro, G. G. and Heldt, E. (2014). Effect of cognitive-behavioral group therapy for panic disorder in changing coping strategies. *Comprehensive Psychiatry*, 55, 87–92. doi:10.1016/j.comppsych.2013.06.008
- Woody, S. R. and Adessky, R. S. (2002). Therapeutic alliance, group cohesion and homework compliance during cognitive behavioural group treatment of social phobia. *Behaviour Therapy*, 33, 5–27. doi: 10.1016/S0005-7894 (02) 80003-X
- Yalom, I. D. and Leszcz, M. (2006). Psicoterapia de grupo: teoria e prática (5th ed.) Porto Alegre: Artmed.